MetNET-2: Lanreotide + Metformin in Advanced Well-differentiated GI or Lung Carcinoids

Phase 2, open-label, single-arm trial of lanreotide and metformin in gastrointestinal neuroendocrine tumor and apudoma (NET), sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Primary endpoint: Incidence of serious adverse events and adverse events, physical examination findings, laboratory test abnormalities, and cardiologic assessment abnormalities during the treatment period. Planned start Apr 2016; status: authorised.